With global cancer incidence rising and a strong clinical pipeline exploring combination therapies, the XPOVIO addressable market is expanding. Despite competition from CAR-T and novel therapies, XPOVIO’s oral administration and unique mechanism offer differentiation. LAS […]
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telus International To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telus International […]
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Block To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Block between February […]
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Pacira between August […]
On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in direct competition with another Japanese […]
